NO328470B1 - Vektor for a uttrykke en sekvens i en tumorcelle og vertcelle omfattende denne, samt fremgangsmater for a uttrykke sekvensen in vitro og anvendelse av vektoren for fremstilling av et medikament for behandling av cancer. - Google Patents
Vektor for a uttrykke en sekvens i en tumorcelle og vertcelle omfattende denne, samt fremgangsmater for a uttrykke sekvensen in vitro og anvendelse av vektoren for fremstilling av et medikament for behandling av cancer. Download PDFInfo
- Publication number
- NO328470B1 NO328470B1 NO20001684A NO20001684A NO328470B1 NO 328470 B1 NO328470 B1 NO 328470B1 NO 20001684 A NO20001684 A NO 20001684A NO 20001684 A NO20001684 A NO 20001684A NO 328470 B1 NO328470 B1 NO 328470B1
- Authority
- NO
- Norway
- Prior art keywords
- sequence
- gene
- vector
- expression
- promoter
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 71
- 210000004881 tumor cell Anatomy 0.000 title claims abstract description 42
- 238000000034 method Methods 0.000 title claims abstract description 38
- 201000011510 cancer Diseases 0.000 title claims abstract description 35
- 210000004027 cell Anatomy 0.000 title claims description 137
- 239000013598 vector Substances 0.000 title claims description 87
- 239000003814 drug Substances 0.000 title claims description 15
- 229940079593 drug Drugs 0.000 title claims description 13
- 238000000338 in vitro Methods 0.000 title claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 113
- 230000001105 regulatory effect Effects 0.000 claims abstract description 58
- 231100000433 cytotoxic Toxicity 0.000 claims abstract description 17
- 230000001472 cytotoxic effect Effects 0.000 claims abstract description 17
- 239000003623 enhancer Substances 0.000 claims description 53
- 239000002773 nucleotide Substances 0.000 claims description 34
- 125000003729 nucleotide group Chemical group 0.000 claims description 34
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 26
- 239000013612 plasmid Substances 0.000 claims description 26
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 24
- 206010005003 Bladder cancer Diseases 0.000 claims description 21
- 108091033319 polynucleotide Proteins 0.000 claims description 16
- 102000040430 polynucleotide Human genes 0.000 claims description 16
- 239000002157 polynucleotide Substances 0.000 claims description 16
- 108091092562 ribozyme Proteins 0.000 claims description 16
- 108090000994 Catalytic RNA Proteins 0.000 claims description 15
- 102000053642 Catalytic RNA Human genes 0.000 claims description 15
- 108091026890 Coding region Proteins 0.000 claims description 13
- 102000006601 Thymidine Kinase Human genes 0.000 claims description 10
- 108020004440 Thymidine kinase Proteins 0.000 claims description 10
- 230000000692 anti-sense effect Effects 0.000 claims description 10
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 10
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 8
- -1 pseudomonatoxin Proteins 0.000 claims description 8
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 201000001531 bladder carcinoma Diseases 0.000 claims description 6
- 208000010570 urinary bladder carcinoma Diseases 0.000 claims description 6
- 101150090188 Cdk8 gene Proteins 0.000 claims description 5
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 5
- 102000009016 Cholera Toxin Human genes 0.000 claims description 5
- 108010049048 Cholera Toxin Proteins 0.000 claims description 5
- 241000514744 Cyclina Species 0.000 claims description 5
- 102000016607 Diphtheria Toxin Human genes 0.000 claims description 5
- 108010053187 Diphtheria Toxin Proteins 0.000 claims description 5
- 101150029707 ERBB2 gene Proteins 0.000 claims description 5
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 claims description 5
- 102100027584 Protein c-Fos Human genes 0.000 claims description 5
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 claims description 5
- 108010039491 Ricin Proteins 0.000 claims description 5
- 101150112625 SSN3 gene Proteins 0.000 claims description 5
- 101100150415 Schizosaccharomyces pombe (strain 972 / ATCC 24843) srb10 gene Proteins 0.000 claims description 5
- 102100023132 Transcription factor Jun Human genes 0.000 claims description 5
- 101150073031 cdk2 gene Proteins 0.000 claims description 5
- 201000005296 lung carcinoma Diseases 0.000 claims description 5
- 231100000590 oncogenic Toxicity 0.000 claims description 5
- 230000002246 oncogenic effect Effects 0.000 claims description 5
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 claims description 5
- 206010003571 Astrocytoma Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 101100005789 Caenorhabditis elegans cdk-4 gene Proteins 0.000 claims description 4
- 206010029260 Neuroblastoma Diseases 0.000 claims description 4
- 239000000824 cytostatic agent Substances 0.000 claims description 4
- 230000001085 cytostatic effect Effects 0.000 claims description 4
- 208000006359 hepatoblastoma Diseases 0.000 claims description 4
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 4
- OQRXBXNATIHDQO-UHFFFAOYSA-N 6-chloropyridine-3,4-diamine Chemical compound NC1=CN=C(Cl)C=C1N OQRXBXNATIHDQO-UHFFFAOYSA-N 0.000 claims description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 3
- 102000000496 Carboxypeptidases A Human genes 0.000 claims description 3
- 108010080937 Carboxypeptidases A Proteins 0.000 claims description 3
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims description 3
- 108010020076 Cytochrome P-450 CYP2B1 Proteins 0.000 claims description 3
- 102000000311 Cytosine Deaminase Human genes 0.000 claims description 3
- 108010080611 Cytosine Deaminase Proteins 0.000 claims description 3
- 208000009889 Herpes Simplex Diseases 0.000 claims description 3
- 102000004459 Nitroreductase Human genes 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 101710101148 Probable 6-oxopurine nucleoside phosphorylase Proteins 0.000 claims description 3
- 102000030764 Purine-nucleoside phosphorylase Human genes 0.000 claims description 3
- 101710132082 Pyrimidine/purine nucleoside phosphorylase Proteins 0.000 claims description 3
- 108700025701 Retinoblastoma Genes Proteins 0.000 claims description 3
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 3
- 208000033781 Thyroid carcinoma Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 102100033220 Xanthine oxidase Human genes 0.000 claims description 3
- 108010093894 Xanthine oxidase Proteins 0.000 claims description 3
- 201000008275 breast carcinoma Diseases 0.000 claims description 3
- 208000019065 cervical carcinoma Diseases 0.000 claims description 3
- 108010079940 cyanogenic beta-glucosidase Proteins 0.000 claims description 3
- 201000005619 esophageal carcinoma Diseases 0.000 claims description 3
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 3
- 108020001162 nitroreductase Proteins 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 208000013077 thyroid gland carcinoma Diseases 0.000 claims description 3
- 102000002464 Galactosidases Human genes 0.000 claims description 2
- 108010093031 Galactosidases Proteins 0.000 claims description 2
- 102000013537 Thymidine Phosphorylase Human genes 0.000 claims 1
- 230000014509 gene expression Effects 0.000 abstract description 98
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 abstract description 32
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 abstract description 26
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 abstract description 11
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 abstract description 8
- 239000000203 mixture Substances 0.000 abstract description 7
- 230000002103 transcriptional effect Effects 0.000 abstract description 2
- 108700008625 Reporter Genes Proteins 0.000 description 24
- 239000012634 fragment Substances 0.000 description 22
- 108060001084 Luciferase Proteins 0.000 description 20
- 108020004414 DNA Proteins 0.000 description 19
- 239000005089 Luciferase Substances 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 19
- 108020004999 messenger RNA Proteins 0.000 description 19
- 230000000694 effects Effects 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 16
- 201000005112 urinary bladder cancer Diseases 0.000 description 15
- 230000001965 increasing effect Effects 0.000 description 14
- 239000000523 sample Substances 0.000 description 14
- 238000001415 gene therapy Methods 0.000 description 13
- 238000001890 transfection Methods 0.000 description 13
- 230000000295 complement effect Effects 0.000 description 12
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 11
- 238000001476 gene delivery Methods 0.000 description 11
- 239000013603 viral vector Substances 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 10
- 238000013518 transcription Methods 0.000 description 10
- 230000035897 transcription Effects 0.000 description 10
- 108091034117 Oligonucleotide Proteins 0.000 description 9
- 241000700605 Viruses Species 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 150000007523 nucleic acids Chemical class 0.000 description 9
- 238000013519 translation Methods 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 241000701161 unidentified adenovirus Species 0.000 description 8
- 108700028369 Alleles Proteins 0.000 description 7
- 101100297347 Caenorhabditis elegans pgl-3 gene Proteins 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- 238000011144 upstream manufacturing Methods 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 6
- 239000000651 prodrug Substances 0.000 description 6
- 229940002612 prodrug Drugs 0.000 description 6
- 108700012359 toxins Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000005520 cutting process Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000013613 expression plasmid Substances 0.000 description 5
- 230000001177 retroviral effect Effects 0.000 description 5
- 238000010561 standard procedure Methods 0.000 description 5
- 241000702421 Dependoparvovirus Species 0.000 description 4
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 4
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 241000700584 Simplexvirus Species 0.000 description 4
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 4
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 231100000599 cytotoxic agent Toxicity 0.000 description 4
- 239000002254 cytotoxic agent Substances 0.000 description 4
- 229940127089 cytotoxic agent Drugs 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 4
- 229960002963 ganciclovir Drugs 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000007901 in situ hybridization Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 3
- 108020005544 Antisense RNA Proteins 0.000 description 3
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 241000589516 Pseudomonas Species 0.000 description 3
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 3
- 239000000074 antisense oligonucleotide Substances 0.000 description 3
- 238000012230 antisense oligonucleotides Methods 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003184 complementary RNA Substances 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000008774 maternal effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 239000013607 AAV vector Substances 0.000 description 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 2
- 241000701822 Bovine papillomavirus Species 0.000 description 2
- 208000006332 Choriocarcinoma Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 108010039918 Polylysine Proteins 0.000 description 2
- 108020004518 RNA Probes Proteins 0.000 description 2
- 239000003391 RNA probe Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 241000251131 Sphyrna Species 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 102100031372 Thymidine phosphorylase Human genes 0.000 description 2
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 2
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 2
- 108700005077 Viral Genes Proteins 0.000 description 2
- 208000008383 Wilms tumor Diseases 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000005014 ectopic expression Effects 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000008175 fetal development Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 210000004779 membrane envelope Anatomy 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 230000003169 placental effect Effects 0.000 description 2
- 229920000656 polylysine Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 210000002993 trophoblast Anatomy 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 101150028074 2 gene Proteins 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- GOILPRCCOREWQE-UHFFFAOYSA-N 6-methoxy-7h-purine Chemical compound COC1=NC=NC2=C1NC=N2 GOILPRCCOREWQE-UHFFFAOYSA-N 0.000 description 1
- 101150106774 9 gene Proteins 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 229910014813 CaC2 Inorganic materials 0.000 description 1
- 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 description 1
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000399988 Carinoma Species 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 101100084900 Drosophila melanogaster Rpn11 gene Proteins 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 102000002494 Endoribonucleases Human genes 0.000 description 1
- 108010093099 Endoribonucleases Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 206010017708 Ganglioneuroblastoma Diseases 0.000 description 1
- 208000032320 Germ cell tumor of testis Diseases 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 108010026389 Gramicidin Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101100452299 Homo sapiens IGF1 gene Proteins 0.000 description 1
- 101100286576 Homo sapiens IGF2 gene Proteins 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 108700005090 Lethal Genes Proteins 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108020001621 Natriuretic Peptide Proteins 0.000 description 1
- 102000004571 Natriuretic peptide Human genes 0.000 description 1
- 241001057495 Neda Species 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 201000007131 Placental site trophoblastic tumor Diseases 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000004389 Ribonucleoproteins Human genes 0.000 description 1
- 108010081734 Ribonucleoproteins Proteins 0.000 description 1
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 241000223892 Tetrahymena Species 0.000 description 1
- 102100028509 Transcription factor IIIA Human genes 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000002215 arabinonucleoside Substances 0.000 description 1
- 238000011717 athymic nude mouse Methods 0.000 description 1
- 108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- CRFNGMNYKDXRTN-CITAKDKDSA-N butyryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CRFNGMNYKDXRTN-CITAKDKDSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 101150055766 cat gene Proteins 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000012191 childhood neoplasm Diseases 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 210000002987 choroid plexus Anatomy 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 108091092330 cytoplasmic RNA Proteins 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000000408 embryogenic effect Effects 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 108010052305 exodeoxyribonuclease III Proteins 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- IUAYMJGZBVDSGL-XNNAEKOYSA-N gramicidin S Chemical compound C([C@@H]1C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CCCN)C(=O)N[C@H](C(N[C@H](CC=2C=CC=CC=2)C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(C)C)C(=O)N1)C(C)C)=O)CC(C)C)C(C)C)C1=CC=CC=C1 IUAYMJGZBVDSGL-XNNAEKOYSA-N 0.000 description 1
- 229950009774 gramicidin s Drugs 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 208000023525 immature teratoma Diseases 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002743 insertional mutagenesis Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000007154 intracellular accumulation Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000032575 lytic viral release Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 201000000289 malignant teratoma Diseases 0.000 description 1
- 210000000415 mammalian chromosome Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 239000000692 natriuretic peptide Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- XKLJHFLUAHKGGU-UHFFFAOYSA-N nitrous amide Chemical compound ON=N XKLJHFLUAHKGGU-UHFFFAOYSA-N 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000001821 nucleic acid purification Methods 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000008775 paternal effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000028742 placenta development Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 208000002918 testicular germ cell tumor Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 208000029387 trophoblastic neoplasm Diseases 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 101150061422 yip5 gene Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94360897A | 1997-10-03 | 1997-10-03 | |
| PCT/IL1998/000486 WO1999018195A2 (en) | 1997-10-03 | 1998-10-04 | Methods and compositions for inducing tumor-specific cytotoxicity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20001684D0 NO20001684D0 (no) | 2000-03-31 |
| NO20001684L NO20001684L (no) | 2000-06-02 |
| NO328470B1 true NO328470B1 (no) | 2010-02-22 |
Family
ID=25479934
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20001684A NO328470B1 (no) | 1997-10-03 | 2000-03-31 | Vektor for a uttrykke en sekvens i en tumorcelle og vertcelle omfattende denne, samt fremgangsmater for a uttrykke sekvensen in vitro og anvendelse av vektoren for fremstilling av et medikament for behandling av cancer. |
| NO20093194A NO331723B1 (no) | 1997-10-03 | 2009-10-22 | Vektor som kan utrykke et cytotoksisk genprodukt samt anvendelse av en slik vektor for fremstilling av et preparat for behandling av kreft |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20093194A NO331723B1 (no) | 1997-10-03 | 2009-10-22 | Vektor som kan utrykke et cytotoksisk genprodukt samt anvendelse av en slik vektor for fremstilling av et preparat for behandling av kreft |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US6087164A (zh) |
| EP (1) | EP1019499B1 (zh) |
| JP (3) | JP5153031B2 (zh) |
| KR (1) | KR100524262B1 (zh) |
| CN (1) | CN1229496C (zh) |
| AT (1) | ATE407948T1 (zh) |
| AU (1) | AU755774B2 (zh) |
| BR (1) | BR9812717B1 (zh) |
| CA (1) | CA2308124C (zh) |
| CZ (2) | CZ294941B6 (zh) |
| DE (1) | DE69840001D1 (zh) |
| HU (1) | HU228470B1 (zh) |
| IL (1) | IL135430A0 (zh) |
| NO (2) | NO328470B1 (zh) |
| PL (1) | PL339949A1 (zh) |
| RU (1) | RU2214280C2 (zh) |
| WO (1) | WO1999018195A2 (zh) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040006220A1 (en) * | 2002-07-02 | 2004-01-08 | Isis Pharmaceuticals Inc. | Antisense modulation of insulin-like growth factor 2 expression |
| US7041654B2 (en) | 1997-10-03 | 2006-05-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods and compositions for inducing tumor-specific cytotoxicity |
| DE19956568A1 (de) * | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| CA2365901A1 (en) * | 1999-04-14 | 2000-10-19 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
| DE19928342A1 (de) * | 1999-06-21 | 2000-12-28 | Deutsches Krebsforsch | Vektoren zur gentherapeutischen Tumorbehandlung |
| US7829693B2 (en) * | 1999-11-24 | 2010-11-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
| WO2002046449A2 (en) * | 2000-12-07 | 2002-06-13 | The Penn State Research Foundation | Selection of catalytic nucleic acids targeted to infectious agents |
| US8546143B2 (en) | 2001-01-09 | 2013-10-01 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
| US20040005567A1 (en) * | 2002-07-02 | 2004-01-08 | Isis Pharmaceuticals Inc. | Antisense modulation of cyclin-dependent kinase 4 expression |
| AU2003241985A1 (en) * | 2002-05-31 | 2003-12-19 | Medinet Co., Ltd. | Dna inducing cancer cell-specific expression and cancer cell-specific expression vector |
| US20040180844A1 (en) * | 2003-03-10 | 2004-09-16 | Fesik Stephen W. | Method of killing cancer cells |
| US20040220085A1 (en) * | 2003-05-02 | 2004-11-04 | Jasbir Sandhu | Compositions for nucleic acid delivery |
| US20040219099A1 (en) * | 2003-05-02 | 2004-11-04 | Jasbir Sandhu | Method for the treatment of tumors |
| US7482156B2 (en) * | 2003-10-15 | 2009-01-27 | Cell Genesys, Inc. | Hepatocellular carcinoma specific promoter and uses thereof |
| US7063947B2 (en) * | 2004-04-08 | 2006-06-20 | Promogen, Inc. | System for producing synthetic promoters |
| US7429482B2 (en) * | 2005-01-13 | 2008-09-30 | United States Of America As Represented By The Department Of Veterans Affairs | Screening tools for discovery of novel anabolic agents |
| EP1915448B1 (en) | 2005-07-07 | 2013-09-04 | Yissum Research Development Company, of The Hebrew University of Jerusalem | Nucleic acid agents for downregulating h19, and methods of using same |
| DE602006014009D1 (de) | 2005-09-22 | 2010-06-10 | Yissum Res Dev Co | Nukleinsäure konstrukten, pharmazeutische kompositionen und methoden für die behandlung von krebs |
| CA2675967A1 (en) * | 2007-01-16 | 2008-07-24 | Yissum Research Development Company Of The Hebrew University Of Jerusale M | Nucleic acid constructs and methods for specific silencing of h19 |
| CA2715080C (en) | 2007-09-28 | 2021-09-28 | Intrexon Corporation | Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof |
| WO2009053982A1 (en) * | 2007-10-25 | 2009-04-30 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Constructs containing multiple expression cassettes for cancer therapy |
| EP2298866A4 (en) * | 2008-07-02 | 2013-11-20 | Otsuka Pharma Co Ltd | ARTIFICIAL KIDNEY PRECURSOR AND METHOD FOR PRODUCING THE SAME |
| US8492133B2 (en) | 2009-01-20 | 2013-07-23 | Ramot At Tel Aviv University, Ltd. | MIR-21 promoter driven targeted cancer therapy |
| EA016223B1 (ru) * | 2009-10-07 | 2012-03-30 | Учреждение Российской Академии Наук Институт Молекулярной Генетики Ран | Способ и генная конструкция для высокоспецифичного ингибирования нежелательного роста клеток |
| WO2016178233A1 (en) * | 2015-05-05 | 2016-11-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Nucleic acid-cationic polymer compositions and methods of making and using the same |
| BR112020021962A2 (pt) * | 2018-04-30 | 2021-01-26 | Amicus Therapeutics, Inc. | construtos para terapia gênica e métodos de uso |
| CN110714075B (zh) * | 2018-07-13 | 2024-05-03 | 立森印迹诊断技术（无锡）有限公司 | 一种用于检测肺肿瘤良恶性程度的分级模型及其应用 |
| CN111206093A (zh) * | 2018-11-21 | 2020-05-29 | 立森印迹诊断技术（无锡）有限公司 | 一种用于检测浸润性膀胱癌的标志物及其应用 |
| CN109609505A (zh) * | 2019-01-14 | 2019-04-12 | 中国科学院成都生物研究所 | 一种体内筛选的剪切rna的锤头状核酶 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2699191B1 (fr) * | 1992-12-16 | 1995-02-10 | Univ Paris Curie | Nouveaux vecteurs rétroviraux, lignées cellulaires les contenant, et leur utilisation dans le traitement des tumeurs. |
| US5631236A (en) * | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
| IL108879A (en) * | 1994-03-07 | 2000-08-31 | Yissum Res Dev Co | Diagnostic assay for malignancies using the H19 gene and kit |
| FR2723697B1 (fr) * | 1994-08-17 | 1996-09-20 | Rhone Poulenc Rorer Sa | Methode de traitement de la restenose par la therapie genique |
| FR2725213B1 (fr) * | 1994-10-04 | 1996-11-08 | Rhone Poulenc Rorer Sa | Vecteurs viraux et utilisation en therapie genique |
-
1998
- 1998-10-01 US US09/165,240 patent/US6087164A/en not_active Expired - Lifetime
- 1998-10-04 HU HU0003745A patent/HU228470B1/hu unknown
- 1998-10-04 CA CA002308124A patent/CA2308124C/en not_active Expired - Lifetime
- 1998-10-04 AT AT98947759T patent/ATE407948T1/de not_active IP Right Cessation
- 1998-10-04 BR BRPI9812717-9A patent/BR9812717B1/pt not_active IP Right Cessation
- 1998-10-04 WO PCT/IL1998/000486 patent/WO1999018195A2/en active IP Right Grant
- 1998-10-04 CZ CZ2004741A patent/CZ294941B6/cs not_active IP Right Cessation
- 1998-10-04 CZ CZ20001201A patent/CZ294694B6/cs not_active IP Right Cessation
- 1998-10-04 DE DE69840001T patent/DE69840001D1/de not_active Expired - Lifetime
- 1998-10-04 AU AU94571/98A patent/AU755774B2/en not_active Expired
- 1998-10-04 PL PL98339949A patent/PL339949A1/xx unknown
- 1998-10-04 IL IL13543098A patent/IL135430A0/xx active IP Right Grant
- 1998-10-04 JP JP2000514993A patent/JP5153031B2/ja not_active Expired - Lifetime
- 1998-10-04 RU RU2000111553/14A patent/RU2214280C2/ru active
- 1998-10-04 EP EP98947759A patent/EP1019499B1/en not_active Expired - Lifetime
- 1998-10-04 CN CNB988118335A patent/CN1229496C/zh not_active Expired - Lifetime
- 1998-10-04 KR KR10-2000-7003609A patent/KR100524262B1/ko not_active IP Right Cessation
-
2000
- 2000-03-31 NO NO20001684A patent/NO328470B1/no not_active IP Right Cessation
- 2000-05-10 US US09/568,059 patent/US6306833B1/en not_active Expired - Lifetime
-
2006
- 2006-05-24 JP JP2006144648A patent/JP2006304801A/ja not_active Withdrawn
-
2007
- 2007-10-18 JP JP2007270777A patent/JP2008136480A/ja active Pending
-
2009
- 2009-10-22 NO NO20093194A patent/NO331723B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO331723B1 (no) | Vektor som kan utrykke et cytotoksisk genprodukt samt anvendelse av en slik vektor for fremstilling av et preparat for behandling av kreft | |
| KR20210102882A (ko) | 핵산 구조체 및 사용 방법 | |
| JP2005522225A (ja) | 亢進された遺伝子発現系 | |
| US7041654B2 (en) | Methods and compositions for inducing tumor-specific cytotoxicity | |
| JP2001520875A (ja) | 血管新生の刺激のための遺伝子治療 | |
| JP4528446B2 (ja) | 前立腺特異的膜抗原遺伝子のイントロン３を含む調節構築物 | |
| CN113557010A (zh) | 用于递送治疗剂的腺相关病毒载体 | |
| CN113874512A (zh) | 诱导毛细胞分化的组合物和方法 | |
| WO2022167009A1 (zh) | 靶向Aqp1 mRNA的sgRNA及其载体与应用 | |
| US20230391836A1 (en) | Amino acid sequence that can destroy cells, and related nucleotide sequence and related uses thereof | |
| Qin et al. | The 3′-end of the human β-actin gene enhances activity of the β-actin expression vector system: construction of improved vectors | |
| EP1305409B1 (en) | Renal regulatory elements and methods of use thereof | |
| WO1999050411A2 (en) | Tumour-specific expression control region and the use thereof | |
| IL135430A (en) | Use of a polynucleotide capable of expressing a cytotoxic gene product in the production of a pharmaceutical composition for treating tumors | |
| MXPA00003251A (en) | Methods and compositions for inducing tumor-specific cytotoxicity | |
| JP2003529321A (ja) | Ｐ−ｈｙｄｅファミリーの単離された核酸、ｐ−ｈｙｄｅタンパク質、及び癌における細胞死の誘導に対する感受性を誘導する方法 | |
| CN117836420A (zh) | 重组tert编码病毒基因组和运载体 | |
| AU2001269862B2 (en) | Renal regulatory elements and methods of use thereof | |
| AU2002343189A1 (en) | Methods and compositions for inducing tumor-specific cytotoxicity | |
| AU2001269862A1 (en) | Renal regulatory elements and methods of use thereof | |
| JP2000217578A (ja) | Ｍａｓｌ１遺伝子 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |